Health

FDA approves AliveCor’s heart arrhythmia-detecting app algorithm

Above: AliveCor's ECG app.

Image Credit: AliveCor

While the step counters and run tracker apps of the world get most of the attention, a growing number of apps in the marketplace are serving serious clinical needs.

One is AliveCor‘s AliveECG app, which will soon run an algorithm that detects atrial fibrillation (AF), a serious type of heart arrhythmia that’s often a precursor to stroke. For people with a history or heart trouble, or atrial fibrillation specifically, the app and the algorithm could provide a life-saving early warning system.

San Francisco-based AliveCor went through a rigorous process with the Food and Drug Administration to prove the accuracy and efficacy of the algorithm. The FDA is particularly interested in reviewing apps that provide any type of actionable, diagnostic information to users, as AliveCor’s app clearly does.

AliveCor's heart monitor nodule attached to an iPhone.

Above: AliveCor’s heart monitor nodule attached to an iPhone.

Image Credit: AliveCor

The AliveECG app runs on a smartphone. The patient places their hand over an AliveCor nodule device that fits over the back of the phone. The app then measures the electric signals being transmitted by the heart and radiating through the fingers, detected by the nodule.

There are lots of types of arrhythmia, but when the algorithm sees patterns in the electrocardiogram (ECG) that are consistent with atrial fibrillation, it can alert the user. The user can then confirm the result by sending their ECG from their smartphone to a medical group in Los Angeles where a board-certified cardiologist can verify the result within 24 hours. This costs the user $12, all of which goes to the medical group.

There is also an option for a technician to read the ECG and return a result within half an hour, AliveCor CEO Euan Thomson told VentureBeat. The user can also send the ECG to his or her own physician.

Thomson says the FDA approval was based in part on the experience of the 6000 or so people who use AliveCor’s device and app. Thomson, himself a medical physicist, says his company has collected a large database of ECG readings from the app. Users can choose whether or not to contribute their results to the database.

The new algorithm will be made available in the (free) AliveECG app in September, Thomson says. The $199 AliveCor monitor device, which users buy at the AliveCor site, has versions that can connect to six recent iOS devices, four Samsung Android phones, and one HTC Android phone.

More information:

Powered by VBProfiles


HealthBeat — VentureBeat’s breakthrough health tech event — is returning on Oct 27-28 in San Francisco. This year’s theme is “The connected age: Integrating data, big & small.” We’re putting long-established giants of the health care world on stage with CEOs of the nation's most disruptive health tech companies to share insights, analyze trends, and showcase breakthrough products. Purchase one of the first 50 tickets and save $400!
14 comments
DrDave01
DrDave01

@ashul Do you think in 2014, "take these meds and come back in 3-6 mos" is how to best manage a dz like with lifestyle triggers?

ashul
ashul

@DrDave01 Agree that management could be completely changed. Ex: Easier to determine AF burden after initiation of new AA or ablation.

DrDave01
DrDave01

@ashul Management done remotely and in real-time. Make like T1DM with @AliveCor ECG like the glucometer. Persinalize meds & lifestyle

ashul
ashul

@DrDave01 Might be a bit overzealous. AF generally doesn't require tight regulation needed in DM, but agreed better mgmt needed overall

DrDave01
DrDave01

@ashul You mean it has not been treated that way. @PrashSanders data shows wt and other lifestyle metrics are VIP. Pt engagement in care key